相关实验视频

Updated: Jul 10, 2025

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

口服塞马格卢提德的有效性,安全性和患者满意度:第一个单中心临床经验

Miodrag Janić^1,2, Marija Jovanović², Andrej Janež^1,2

¹Clinical Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia.

The Journal of international medical research

|November 21, 2023

概括

在斯洛文尼亚的2型糖尿病患者中,口服塞马格卢提德有效降低了血糖和体重. 这种一流的口服药物表现出高患者满意度和良好的安全性.

科学领域:

内分泌学在内分泌学.
代谢疾病代谢疾病
药理学药理学是指药理学的学科.

背景情况:

2型糖尿病 (T2DM) 是一个重大的全球健康挑战.
有效的血糖控制和体重管理对于T2DM患者的治疗结果至关重要.
为了改善T2DM管理,不断寻求新型治疗剂.

研究的目的:

评估斯洛文尼亚T2DM患者口服赛马格卢提德的实际有效性.
为了评估血糖参数 (HbA1c,禁食葡萄糖) 和体重的变化.
为了确定患者的满意度和口服赛马格卢提德的安全概况.

主要方法:

一项前性,开放的干预研究,涉及T2DM患者,这些患者有资格接受口服赛马格卢提德.
患者接受了口服赛马格卢提德 (7和14毫克) 的升级剂量.
在基线,1个月和3-5个月收集的数据,包括HbA1c,禁食葡萄糖,体重,患者满意度 (TSQM) 和不良事件.

主要成果:

口服塞马格卢提德显著降低了HbA1c和空腹血葡萄糖水平.
14毫克的剂量导致体重显著下降.
患者报告高满意度和易用性;轻度,短暂的胃肠道不良反应被注意到.

结论:

口服塞马格卢提德是第一种口服GLP-1受体激动剂,在斯洛文尼亚的最初接受者中显示出有效性,安全性和高患者满意度.
结果支持其在临床实践中用于T2DM管理的实用性.
由于样本规模较小,缺乏安慰剂对照,随访时间较短,因此需要进一步调查.

关键词:

口服塞马格卢提德的使用方法负面影响负面影响身体重量体重体重血糖控制血糖控制血糖控制患者的满意度患者的满意度 2 型糖尿病 2 型糖尿病

更多相关视频

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea

Published on: November 9, 2016

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...